Agennix AG (FRANKFURT: AGX) announced that the next stage of the FORTIS-M trial has begun, with the first patient being dosed in Europe. FORTIS-M is a Phase 3 registration trial evaluating oral talactoferrin versus placebo in advanced non-small cell lung … (source: Medical News Today) RSS feeds and Widgets and RSS feeds – au.feedzilla.com
Tags:breast cancer,colon cancer,health and beauty products mall,liver cancer,lung cancer,ovarian cancer,skin cancer,Womens Health
|
Dont stay trapped in a world of Stress and Anxciety or suffer from Low Self Esteem.
|
